Article Sidebar

pdf
Date Published: 24/11/2023
Abstract Views: 76
Views pdf: 62
DOI: https://doi.org/10.51298/vmj.v532i1.7307
Issue
Vol. 532 No. 1 (2023)
Section
Các bài báo
How to Cite
Đỗ, A. T., Nguyễn, X. H., & Nguyễn, Đình L. (2023). TIME TO TREATMENT FAILURE IN METASTATIC PROSTATE CANCER TREATED WITH SEQUENTIAL ADT AND ADT PLUS ABIRATERONE ACETATE. Vietnam Medical Journal, 532(1). https://doi.org/10.51298/vmj.v532i1.7307

TIME TO TREATMENT FAILURE IN METASTATIC PROSTATE CANCER TREATED WITH SEQUENTIAL ADT AND ADT PLUS ABIRATERONE ACETATE

Anh Tú Đỗ1,, Xuân Hậu Nguyễn2, Đình Lợi Nguyễn2
1 K Hospital
2 HMU

Main Article Content

Abstract

Background: Our study evaluated time to treatment failure of patients with metastatic prostate cancer (mPCa) received sequential ADT and ADT plus Abiraterone acetate (AAP). Methods: This retrospective, observational study collected data from metastatic prostate cancer treated with sequential ADT and ADT plus Abiraterone acetate in Vietnam National Cancer Hospital. Kaplan-Meier curves were used to estimate time to treatment failure (TTF). The impact of baseline characteristics on TTF was explored using univariate and multivariate Cox proportional hazard models. Results: Data from 65 eligible patients were analyzed. The median age was 67 years (interquartile range [IQR]: 62–74). The rate of patients de novo was 75,4%, Gleason ≥ 8 was 78,5%, and ECOG PS ≥ 2 was 24,6%. The rate of patients with high burden was 46,2%. The median PSA was 150,6 ng/ml (IQR: 41,6-292,2). The median time to treatment failure was 34.0 months (95% CI: 24.9-43.0). ECOG PS ≥ 2, and time from ADT start to mCRPC (< 12 months) were predictive factors independent of TTF (p < 0.05). Conclusion: The median time to treatment failure was 34.0 months (95% CI: 24.9-43.0). ECOG PS ≥ 2, and time from ADT start to mCRPC (< 12 months) were predictive factors independent of TTF (p < 0.05

Article Details

Keywords

Metastatic prostate cancer (mPCa), ADT, ADT plus Abiraterone acetate, time to treatment failure.

References

1. Cancer today. , accessed: 05/08/2023.
2. Cancer of the Prostate - Cancer Stat Facts. SEER, , accessed: 05/08/2023.
3. Ryan C.J., Smith M.R., De Bono J.S. và cộng sự. (2013). Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med, 368(2), 138–148.
4. James N.D., Clarke N.W., Cook A. và cộng sự. (2022). Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer, 151(3), 422–434.
5. Humphreys M.R., Fernandes K.A., và Sridhar S.S. (2013). Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC). J Cancer, 4(4), 304–314.
6. Sweeney C.J., Chen Y.-H., Carducci M. và cộng sự. (2015). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med, 373(8), 737–746.
7. Loriot Y., Eymard J.-C., Patrikidou A. và cộng sự. (2015). Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. European Journal of Cancer, 51(14), 1946–1952.
8. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design - The Lancet.